Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway Nasdaq:ATOS

Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway Nasdaq:ATOS

News Highlights

SEATTLE, April 08, 2021 (News) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that an ovarian cancer patient has begun treatment with Atossa’s proprietary oral Endoxifen. The FDA previously issued a “Safe to Proceed” letter under their expanded access pathway, permitting the use of Atossa’s oral Endoxifen in this patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief.

“The patient has recurrent ovarian cancer and did not tolerate tamoxifen, which is sometimes prescribed for ovarian cancer as well as breast cancer,” commented Steven Quay, M.D., Ph.D., Atossa’s President and CEO. “The patient recently underwent functional molecular genomic testing using 3D tumor organoid cultures grown in the laboratory from the patient’s tumor to help determine potential therapies. This testing revealed that the combination of Endoxifen and alpelisib produced an exceptional tumor response. We will follow the progress of this patient and consider additional clinical studies in patients with ovarian cancer.”

Under the FDA expanded access program, the use of Atossa’s proprietary oral Endoxifen is restricted solely to this patient.

About FDA Expanded Access

Sometimes called “compassionate use,” expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. For more information about this process, please see the FDA website: FDA Expanded Use Website

About Atossa’s Proprietary Endoxifen

Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. In third party preclinical studies, endocrine-sensitive and letrozole-resistant breast tumors, Z-endoxifen resulted in robust antitumor and antiestrogenic activity compared to tamoxifen and aromatase inhibitor monotherapy.

Atossa has been developing its proprietary oral Endoxifen for breast cancer and other breast conditions and has successfully completed five clinical studies with this drug, including an expanded access study of a female breast cancer patient who has been taking oral Endoxifen for over two years, with no recurrence to date.

About Ovarian Cancer

In 2021 ovarian cancer will be diagnosed in about 21,400 women in the United States and about 13,770 women will die from the disease. Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.

About Alpelisib

Alpelisib was approved in the United States in 2019 for use in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. PIK3 is a family of lipid kinases and one of them, PIK3CA, has mutations or gene amplification detected in 30.5% of all ovarian cancers and 45% of the endometrioid and clear cell subtypes. Alpelisib is marketed by Novartis under the brand name of Piqray.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim, preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, whether change in mammographic breast density is an approvable end point for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and General CounselOffice: (866) 893-4927kyle.guse@atossainc.com

Investor Relations Contact:Core IROffice:(516) 222-2560ir@atossainc.com

Source: Atossa Therapeutics, Inc.

  • Check the latest Health news updates and information.
  • Please share this news Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway Nasdaq:ATOS with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Who has student loan debt for Biden to cancel?  Surprisingly, millions of boomers

Who has student loan debt for Biden to cancel? Surprisingly, millions of boomers

In 2020, borrowers 50 and older owed $336.1 billion on student loans — 22% of the nation’s total student loan debt. That was more than double the 10% share ...
Strange players are receiving “God Roll” weapons to replace their unlit weapons

Strange players are receiving “God Roll” weapons to replace their unlit weapons

“When running operations of this scale on our database, we want to ensure that there are no instances where a restoration could have a continued significant ...
Armor, launch date for Destiny 2 Guardian Games in 2021

Armor, launch date for Destiny 2 Guardian Games in 2021

So, ahead of the Destiny 2 Guardian Games imminent launch, here’s everything we know about this year’s event. The Destiny 2 Guardian Games 2021 event is ...
Mothers and money: Wonderworks

Mothers and money: Wonderworks

”We also partner with our local community. We do what is called ““Ozart,”” we put something out for students ages 6 to 20 in Missouri and Arkansas. They can ...
PV Financial announces additions to the team

PV Financial announces additions to the team

Post navigation “Having Andrea join our team is a major step in the future success of PV Financial,” said Sokolowski. “Andrea’s talents in social media and ...
Get nearly $500 off this Dell XPS Desktop with RTX 3070 graphics

Get nearly $500 off this Dell XPS Desktop with RTX 3070 graphics

But Dell is here with a deep discount of nearly $500 on its XPS desktop model with RTX 3070 graphics, taking the price down to a scalper-busting $1,409 ...
CVS donated to Dark-Money Group that fights access to health care

CVS donated to Dark-Money Group that fights access to health care

The letter, also signed by the chief executives of Anthem, Cigna, Harvard Pilgrim Health Care, and UnitedHealth Group, charged that the effort to lower ...
Knights Of The Old Republic recast talk

Knights Of The Old Republic recast talk

  The recent history of Star Wars video games has been rather rocky ever since Disney purchased the intellectual property back in 2012. Soon after that ...
Sales surge after New cybersecurity law protects smart devices

Sales surge after New cybersecurity law protects smart devices

New figures commissioned by the government show almost half (49%) of UK residents have purchased at least one smart device since the start of the coronavirus ...
Show next
Compsmag - Latest News from tech, business and health
Logo